Alembic Pharmaceuticals Limited

NSE:APLLTD.NS

1012.1 (INR) • At close July 1, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2025202420232022202120202019201820172016201520142013201220112010
Revenue 66,720.862,286.356,526.252,317.952,762.244,919.738,066.130,350.430,300.630,549.73220,099.68818,201.14914,931.43214,663.87411,989.87511,381.5
Cost of Revenue 17,933.639,59817,088.217,231.915,212.713,141.111,933.810,621.310,372.78,425.6787,582.5287,591.4987,166.2527,079.2026,523.58110,629.4
Gross Profit 48,787.222,688.339,43835,08637,549.531,778.626,132.319,729.119,927.922,124.05412,517.1610,609.6517,765.187,584.6725,466.294752.1
Gross Profit Ratio 0.7310.3640.6980.6710.7120.7070.6860.650.6580.7240.6230.5830.520.5170.4560.066
Reseach & Development Expenses 04,385.6290.7505.9253.8426.4302.7368.69823,070.6291,216.2261,164.322736.328585.822471.3180
General & Administrative Expenses 02,519.72,410.52,109.82,086.61,551.21,350.71,1021,448.7517.355423.505331.937205.138119.48300
Selling & Marketing Expenses 09,968.89,5238,903.86,962.55,311.95,900.43,802.33,931.42,736.7122,446.8791,940.3211,548.521,082.0751,136.5010
SG&A 15,623.412,488.511,933.511,013.69,049.16,863.17,251.14,904.35,380.13,254.0672,870.3842,272.2581,753.6581,201.5581,136.5010
Other Expenses 0-181.527.41.320.22.30.32.56,737.5117.3210.0423,318.014.3722,551.155-56.5
Operating Expenses 15,623.415,869.735,108.929,16024,581.120,66918,558.114,630.614,535.912,766.5538,985.3087,399.8665,624.9355,651.5394,158.97456.5
Operating Income 33,163.85,758.14,377.85,874.712,968.411,114.17,413.25,098.55,3929,357.5013,531.8523,209.7852,140.2451,933.1331,307.32695.6
Operating Income Ratio 0.4970.0920.0770.1120.2460.2470.1950.1680.1780.3060.1760.1760.1430.1320.1090.061
Total Other Income Expenses Net -26,092560.2-338-12,107.7-9,634.8-1,111.4-45.1314.1-107.8-0.958.863-103.673-76.703-313.51-247.401-257.5
Income Before Tax 7,071.86,318.33,545.96,201.113,680.89,998.27,493.25,412.75,253.69,356.0193,590.7153,106.1122,063.5421,609.8241,068.433438.1
Income Before Tax Ratio 0.1060.1010.0630.1190.2590.2230.1970.1780.1730.3060.1790.1710.1380.110.0890.038
Income Tax Expense 1,251.7160126.11,044.62,533.21,991.81,567.51,203.51,221.92,160.148763.491751.028410.995308.498214.55742.7
Net Income 5,834.26,158.23,419.95,209.411,4658,288.25,843.74,126.34,031.77,194.3682,829.2462,355.0841,652.5471,301.326853.876395.4
Net Income Ratio 0.0870.0990.0610.10.2170.1850.1540.1360.1330.2350.1410.1290.1110.0890.0710.035
EPS 29.6831.3317.426.559.1843.973121.8921.3938.1915.0112.498.776.94.532.96
EPS Diluted 29.6831.3317.426.559.1843.973121.8921.3938.1915.0112.498.776.94.532.96
EBITDA 10,082.39,616.77,111.19,246.215,675.711,8438,829.66,501.36,214.110,033.13,993.3033,624.7012,653.0482,321.8061,603.1851,168.8
EBITDA Ratio 0.1510.1540.1260.1770.2970.2640.2320.2140.2050.3280.1990.1990.1780.1580.1340.103